Expert Q&As
First interactions with EMA - Q&A 6
What CMC (Chemistry, Manufacturing, and Controls) expectations in the EU might surprise biopharma companies?
Access decades of experience
What’s Inside the Q&A:
CMC Expectations Unpacked
See why EU regulators demand a more “finished” manufacturing story than their US counterparts.
Data Depth & Readiness
Understand how much earlier Europe expects full stability data, validation, and control strategies.
Specification Standards
Explore how tighter impurity and quality thresholds can reshape your submission timeline.
Avoiding CMC Surprises
Learn how early alignment and proactive validation prevent costly delays at EMA review.
Download our Expert Q&A
Discover our latest news
Expert Q&As
First interactions with EMA - Q&A 1
What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?
Expert Q&As
First interactions with EMA - Q&A 2
How does the EU drug development landscape differ from the US ?
Expert Q&As
First interactions with EMA - Q&A 7
What regulatory pathway missteps should we avoid, and how can we streamline our EU dossier preparation?
